National Institutes of Health: Prostatic Neoplasms trials

The registry lists 202 Prostatic Neoplasms studies with National Institutes of Health as lead sponsor. 25 are open to participants now and 87 have results posted.

Early Phase 1 3Phase 1 50Phase 2 115Phase 3 6No phase 43(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00110214Phase 3Results posted
• A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerCompletedNCT00108732Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate CancerCompletedNCT00103194Phase 2Results posted
• A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate CancerCompletedNCT00090545Phase 2Results posted
• Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate CancerCompletedNCT00089609Phase 2Results posted
• Ixabepilone in Treating Patients With Metastatic Prostate CancerCompletedNCT00087139Phase 2Results posted
• Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate CancerCompletedNCT00080899Phase 2Results posted
• Sequential Vaccinations in Prostate Cancer PatientsCompletedNCT00060528Phase 1/2Results posted
• Perifosine in Treating Patients With Recurrent Prostate CancerTerminatedNCT00058214Phase 2Results posted
• Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate CancerCompletedNCT00040365Phase 2Results posted
• Thalidomide for the Treatment of Hormone-Dependent Prostate CancerCompletedNCT00004635Phase 3Results posted
• Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)Active, not recruitingNCT00002540Not applicableResults posted
• Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesWithdrawnNCT06982222Phase 1
• Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided BiopsyTerminatedNCT05872503
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerActive, not recruitingNCT05828082Phase 2
• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnNCT05807126Phase 1
• N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerWithdrawnNCT05445882Phase 2
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate CancerSuspendedNCT04808427Not applicable
• Evaluation of Atherosclerotic Plaques in Abdominal CT StudiesActive, not recruitingNCT04652973
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• Integrated Genomic Prostate Score With MRI Targeted Prostate BiopsiesActive, not recruitingNCT04541030
• Mobile Sensor Technologies to Assess General Symptomology of People With CancerCompletedNCT04465214
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingNCT04071236Phase 1/2
• Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerActive, not recruitingNCT03976843Phase 2
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyCompletedNCT03707574
• 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate CancerActive, not recruitingNCT03181867Phase 2
• 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate CancerActive, not recruitingNCT03173924Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy ParticipantsCompletedNCT01497431Phase 1
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
• Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate CancerCompletedNCT01296139Phase 1
• The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer DiagnosisCompletedNCT01176526
• Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate CancerCompletedNCT00956163Early Phase 1
• An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated SkinCompletedNCT00923104
• Study of a Polymorphism in Patients With Prostate CancerCompletedNCT00900185
• Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154CompletedNCT00535834
• Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate CancerTerminatedNCT00512668Phase 1
• Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the ProstateCompletedNCT00459407Phase 1
• Lycopene in Healthy Male ParticipantsCompletedNCT00450957Phase 1
• Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate CancerCompletedNCT00450229Phase 1
• Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate CancerCompletedNCT00394511Phase 3
• Agriculture Health StudyActive, not recruitingNCT00352924
• Identification of Prostate Cancer GenesCompletedNCT00342784
• An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian MalesCompletedNCT00342771
• Markers for Early Detection of Prostate CancerCompletedNCT00340717
• Analyses of Human Samples Collected in Clinical TrialsCompletedNCT00339664
• Survey of Prostate Cancer in Accra, GhanaCompletedNCT00339534
• Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone HealthCompletedNCT00200824Phase 2
• Magnetic Resonance Imaging to Evaluate Prostate CancerCompletedNCT00182624
• Vaccine and Antibody Treatment of Prostate CancerCompletedNCT00113984Phase 1
• Vaccine Therapy in Treating Patients With Recurrent Prostate CancerCompletedNCT00109811Phase 2
• Cilengitide in Treating Patients With Metastatic Prostate CancerCompletedNCT00103337Phase 2
• A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive TherapyCompletedNCT00096551Phase 1
• SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or PaclitaxelCompletedNCT00096499Phase 2
• Lapatinib in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT00095667Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the ProstateCompletedNCT00083005Phase 2
• Magnetic Resonance Imaging to Locate and Characterize Prostate CancerCompletedNCT00082147Not applicable
• Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate CancerCompletedNCT00078910Phase 2
• GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid TumorsCompletedNCT00074022Phase 1/2
• Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
• Using Fiducial Markers to Aid in Prostate Cancer Radiation TreatmentCompletedNCT00061347Phase 1
• Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate CancerCompletedNCT00060437Phase 2
• Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00058253Phase 1
• Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate CancerCompletedNCT00058084Phase 2
• Prevention of Osteoporosis in Men With Prostate CancerCompletedNCT00048841Phase 3
• Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate CancerCompletedNCT00045331Not applicable
• Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate CancerCompletedNCT00045227Phase 2
• Gene-Environment Interaction in Prostate CancerCompletedNCT00041847
• BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00040755Phase 2
• Massage Therapy for Cancer-Related FatigueCompletedNCT00039793Phase 2
• Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate CancerCompletedNCT00039624Phase 2
• Zoledronate and BMS-275291 in Treating Patients With Prostate CancerCompletedNCT00039104Phase 2
• Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening ProgramCompletedNCT00035217
• Ketoconazole Plus Docetaxel to Treat Prostate CancerCompletedNCT00032825Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• APC8015 and Bevacizumab in Treating Patients With Prostate CancerCompletedNCT00027599Phase 2
• Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic MethodsCompletedNCT00022919
• Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate CancerCompletedNCT00020254Phase 2
• Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate CancerCompletedNCT00020046Phase 2
• Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate CancerTerminatedNCT00019695Phase 2
• Flavopiridol in Treating Patients With Refractory CancerCompletedNCT00019344Phase 1
• Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate CancerCompletedNCT00016107Phase 2
• A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNAStatus unknownNCT00006430Phase 1
• PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate CancerCompletedNCT00005916Phase 2
• Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate CancerTerminatedNCT00005067Phase 1
• Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)TerminatedNCT00005039Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Vaccine Therapy in Treating Patients With Metastatic Prostate CancerCompletedNCT00004029Phase 1
• Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate CancerCompletedNCT00003832Phase 2
• Flavopiridol in Treating Patients With Recurrent Prostate CancerCompletedNCT00003256Phase 2
• Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate CancerCompletedNCT00002723Phase 3
• Genetic Analysis of Hereditary Prostate CancerCompletedNCT00001469
• A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate CancerCompletedNCT00001446Phase 2
• A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory NeoplasmsCompletedNCT00001444Phase 1
• A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the ProstateCompletedNCT00001382Phase 1